Three-Month Post-Treatment PSA Level as a Biomarker of Treatment Response in Patients With Intermediate- or High-Risk Prostate Cancer Treated With ADT and RT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Three-Month Posttreatment Prostate-Specific Antigen Level as a Biomarker of Treatment Response in Patients With Intermediate-Risk or High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy and Radiotherapy
Cancer 2018 May 04;[EPub Ahead of Print], AK Bryant, AV D'Amico, PL Nguyen, JP Einck, CJ Kane, RR McKay, DR Simpson, AJ Mundt, JD Murphy, BS RoseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.